Top Page
Genflow Biosciences Plc
(LSE:GENF)
Genflow Biosciences Plc (GENF) vs. iShares MSCI United Kingdom ETF (EWC)
Genflow Biosciences Plc Business Overview & Revenue Model
Genflow Biosciences Plc Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -150.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -150.95K | -1.20K | -1.03K | -130.00 | 0.00 | 0.00 |
| EBITDA | -1.27M | -1.59M | -1.80M | -1.33M | -988.10K | -1.09K |
| Net Income | -1.27M | -1.59M | -1.63M | -1.34M | -988.29K | -651.01K |
Balance Sheet | ||||||
| Total Assets | 468.38K | 385.91K | 1.07M | 2.62M | 276.55K | 283.78K |
| Cash, Cash Equivalents and Short-Term Investments | 279.44K | 278.68K | 683.97K | 2.36M | 224.00K | 254.23K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 771.38K | 788.92K | 345.74K | 250.99K | 221.43K | 64.80K |
| Stockholders Equity | -303.00K | -403.01K | 725.91K | 2.37M | 55.12K | 218.98K |
Cash Flow | ||||||
| Free Cash Flow | -1.28M | -1.08M | -1.66M | -1.37M | -747.38K | -439.46K |
| Operating Cash Flow | -1.28M | -1.08M | -1.66M | -1.37M | -747.38K | -439.46K |
| Investing Cash Flow | 372.00 | 0.00 | -2.44K | -2.48K | 198.50K | 216.55K |
| Financing Cash Flow | 865.22K | 656.63K | 0.00 | 3.50M | 783.71K | 1.96M |
Genflow Biosciences Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | £23.60M | -6.25 | -213.66% | ― | 39.88% | 81.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £9.60M | -3.89 | -648.46% | ― | ― | ― | |
46 Neutral | £1.41M | -2.58 | -85.21% | ― | 44.32% | 60.00% | |
44 Neutral | £16.88M | -9.38 | -164.37% | ― | -11.43% | 23.40% | |
41 Neutral | £89.04M | -5.79 | -209.34% | ― | 198.49% | -26.66% | |
38 Underperform | £11.80M | -0.29 | -407.49% | ― | 72.17% | 79.03% |
Genflow Biosciences Plc Corporate Events
Genflow Biosciences reported a year of scientific and clinical progress in 2025, highlighting completion of dosing in its blinded SIRT6-based gene therapy trial in aging dogs without observed adverse events, with initial efficacy data expected in the first quarter of 2026 and longer-term results by mid-year. The company advanced its MASH program by repositioning GF-1002 toward patients with advanced fibrosis, generating new preclinical proof-of-concept data on hepatocellular carcinoma prevention, and exploring mRNA/LNP delivery to enable repeat dosing and reduce costs, while also entering ophthalmology with a glaucoma program aimed at neuroprotection of retinal ganglion cells in a market forecast to reach up to $14 billion in the early 2030s. Additional efforts included steady progress in a sarcopenia program and the ExoFastTrack initiative, both supporting the broader pipeline. Looking to 2026, Genflow plans to rationalize its portfolio around the most promising, partner-attractive assets and pursue early-stage licensing and collaboration deals to secure non-dilutive funding, strengthen its partner ecosystem, and support its transition into a more mature, growth-oriented phase with multiple upcoming data readouts and a growing intellectual property base.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Genflow Biosciences Plc announced the successful completion of the dosing phase in their canine gene therapy trial, with no adverse events reported, indicating a strong safety profile. The trial, which began in March 2025, aims to assess the efficacy of their SIRT6-based gene therapy in extending healthspan, with initial results expected in January 2026 and further assessments in mid-2026. The company plans to explore early-stage licensing opportunities with animal health companies based on the efficacy data.
Genflow Biosciences Plc announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, a major global investment event in the healthcare sector. This participation is seen as a strategic move to engage with potential partners and investors as Genflow advances its gene-therapy pipeline, particularly focusing on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which could open new opportunities in the longevity space.
Genflow Biosciences Plc announced that as of 31 October 2025, the company’s total issued share capital consists of 493,547,942 Ordinary Shares, all with voting rights. This information is crucial for shareholders to determine their notification requirements under the Financial Conduct Authority’s rules, potentially impacting investment decisions and stakeholder engagement.
Genflow Biosciences Plc announced the publication of its second European patent application for a SIRT6 gene variant targeting non-alcoholic steatohepatitis (NASH), marking a significant milestone in its intellectual property portfolio. This development strengthens Genflow’s IP leadership in the longevity and metabolic disease space, establishing a robust European patent framework that supports its therapeutic platform and future clinical programs, thereby enhancing partnership potential and long-term value creation.
Genflow Biosciences Plc announced that the European Patent Office has recognized the patentability of its SIRT6 variant patent, marking a significant milestone in its intellectual property strategy. This development provides provisional protection across participating EPO member states, positioning Genflow to benefit from EU grant opportunities and strengthening its leverage in partnerships with pharmaceutical and biotech companies. The formal recognition of this patent underscores Genflow’s progress in securing its intellectual property and enhances its strategic position for future collaborations and funding.